<DOC>
	<DOC>NCT01648634</DOC>
	<brief_summary>The objective is to determine whether nebivolol, a beta-blockade drug, can prevent the development of heart disease in patients with Duchenne muscular dystrophy aged 10 to 15 year-old.</brief_summary>
	<brief_title>Nebivolol for the Prevention of Left Ventricular Systolic Dysfunction in Patients With Duchenne Muscular Dystrophy</brief_title>
	<detailed_description>A 1.25 mg-test dose will be administrated to assess the treatment tolerance before randomization. A forced titration of nebivolol and placebo will be performed with 2 weeks periods. Full dose of nebivolol and placebo is 5mg/day (7.5mg/day for patients whose weight is&gt;60kg).</detailed_description>
	<mesh_term>Heart Failure</mesh_term>
	<mesh_term>Cardiomyopathies</mesh_term>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy, Duchenne</mesh_term>
	<mesh_term>Nebivolol</mesh_term>
	<criteria>Duchenne muscular dystrophy genetically proven Age between 10 and 15 years Left ventricular ejection fraction assessed by radionuclide angiography ≥50% and measured within 3 months Systolic blood pressure ≥80 mmHg Diastolic blood pressure ≥70 mmHg Heart rate &lt;50 bpm 2nd or 3rd degree atrioventricular blocks, sinus node dysfunction Asthma or bronchospasm Severe peripheral circulatory disease Hypersensitivity to nebivolol or excipients Metabolic acidosis Blood urea &gt;7 mmol/l Liver transaminases enzymes &gt;6 fold the upper limit of normal Formal indication for betablockade treatment Cardiac treatments except angiotensinconverting enzyme inhibitors Participation to another clinical trial within 3 months</criteria>
	<gender>Male</gender>
	<minimum_age>10 Years</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>December 2016</verification_date>
	<keyword>Nebivolol</keyword>
	<keyword>beta-blockade treatment</keyword>
</DOC>